These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 36773193)

  • 21. Impact of MMX® mesalamine on improvement and maintenance of health-related quality of life in patients with ulcerative colitis.
    Hodgkins P; Yen L; Yarlas A; Karlstadt R; Solomon D; Kane S
    Inflamm Bowel Dis; 2013 Feb; 19(2):386-96. PubMed ID: 22648999
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The impact of biological interventions for ulcerative colitis on health-related quality of life.
    LeBlanc K; Mosli MH; Parker CE; MacDonald JK
    Cochrane Database Syst Rev; 2015 Sep; 2015(9):CD008655. PubMed ID: 26393522
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The arthritic patients' perspective of measuring treatment efficacy: Patient Reported Experience Measures (PREMs) as a quality tool.
    El Miedany Y; El Gaafary M; Youssef S; Ahmed I; Palmer D
    Clin Exp Rheumatol; 2014; 32(4):547-52. PubMed ID: 24984075
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Golimumab in real-world practice in patients with ulcerative colitis: Twelve-month results.
    Teich N; Grümmer H; Jörgensen E; Liceni T; Holtkamp-Endemann F; Fischer T; Hohenberger S
    World J Gastroenterol; 2020 Jun; 26(21):2852-2863. PubMed ID: 32550760
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Manitoba IBD Index: evidence for a new and simple indicator of IBD activity.
    Clara I; Lix LM; Walker JR; Graff LA; Miller N; Rogala L; Rawsthorne P; Bernstein CN
    Am J Gastroenterol; 2009 Jul; 104(7):1754-63. PubMed ID: 19455122
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Psychometric validation of the Psoriasis Symptom Diary using Phase III study data from patients with chronic plaque psoriasis.
    Strober B; Zhao Y; Tran MH; Gnanasakthy A; Nyirady J; Papavassilis C; Nelson LM; McLeod LD; Mordin M; Gottlieb AB; Elewski BE; Lebwohl M
    Int J Dermatol; 2016 Mar; 55(3):e147-55. PubMed ID: 26518255
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Translation and evaluation of the simplified Chinese version of the rating form of IBD patient concerns.
    Luo J; Zhong J; Li H; Zhang S; Zhang L; Hou JT; Ke J; Li H; Liu F; Chen XL
    BMC Gastroenterol; 2022 Sep; 22(1):426. PubMed ID: 36138341
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The IMPACT questionnaire: a valid measure of health-related quality of life in pediatric inflammatory bowel disease.
    Otley A; Smith C; Nicholas D; Munk M; Avolio J; Sherman PM; Griffiths AM
    J Pediatr Gastroenterol Nutr; 2002 Oct; 35(4):557-63. PubMed ID: 12394384
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A new functional status outcome measure of dyspnea and anxiety for adults with lung disease: the dyspnea management questionnaire.
    Migliore Norweg A; Whiteson J; Demetis S; Rey M
    J Cardiopulm Rehabil; 2006; 26(6):395-404. PubMed ID: 17135861
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Validation of the EuroQol questionnaire in patients with inflammatory bowel disease.
    König HH; Ulshöfer A; Gregor M; von Tirpitz C; Reinshagen M; Adler G; Leidl R
    Eur J Gastroenterol Hepatol; 2002 Nov; 14(11):1205-15. PubMed ID: 12439115
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The patient simple clinical colitis activity index (P-SCCAI) can detect ulcerative colitis (UC) disease activity in remission: a comparison of the P-SCCAI with clinician-based SCCAI and biological markers.
    Bennebroek Evertsz' F; Nieuwkerk PT; Stokkers PC; Ponsioen CY; Bockting CL; Sanderman R; Sprangers MA
    J Crohns Colitis; 2013 Dec; 7(11):890-900. PubMed ID: 23269224
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Reliability and initial validation of the ulcerative colitis endoscopic index of severity.
    Travis SP; Schnell D; Krzeski P; Abreu MT; Altman DG; Colombel JF; Feagan BG; Hanauer SB; Lichtenstein GR; Marteau PR; Reinisch W; Sands BE; Yacyshyn BR; Schnell P; Bernhardt CA; Mary JY; Sandborn WJ
    Gastroenterology; 2013 Nov; 145(5):987-95. PubMed ID: 23891974
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Psychometric properties of the original Inflammatory Bowel Disease Questionnaire, a Spanish version.
    Vidal A; Gómez-Gil E; Sans M; Portella MJ; Salamero M; Piqué JM; Panés J
    Gastroenterol Hepatol; 2007 Apr; 30(4):212-8. PubMed ID: 17408549
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies.
    Sandborn WJ; Vermeire S; Peyrin-Biroulet L; Dubinsky MC; Panes J; Yarur A; Ritter T; Baert F; Schreiber S; Sloan S; Cataldi F; Shan K; Rabbat CJ; Chiorean M; Wolf DC; Sands BE; D'Haens G; Danese S; Goetsch M; Feagan BG
    Lancet; 2023 Apr; 401(10383):1159-1171. PubMed ID: 36871574
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Validation of a self-reported work disability questionnaire for ulcerative colitis.
    Ramos A; Vergara M; Melcarne L; Sicilia B; Gomollón F; Calvet X
    Medicine (Baltimore); 2018 Sep; 97(39):e12486. PubMed ID: 30278537
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Inflammatory Bowel Disease-Disability Index: validation of the Portuguese version according to the COSMIN checklist.
    Soares JB; Pereira R; Costa JM; Arroja B; Gonçalves R
    Eur J Gastroenterol Hepatol; 2016 Oct; 28(10):1151-60. PubMed ID: 27472270
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Validation of the English version of the difficulty of life scale for patients with ulcerative colitis.
    Kawakami A; Choong LM; Tanaka M; Kunisaki R; Maeda S; Bjarnason I; Hayee B
    Eur J Gastroenterol Hepatol; 2020 Mar; 32(3):312-317. PubMed ID: 31714389
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and Safety of Etrasimod in a Phase 2 Randomized Trial of Patients With Ulcerative Colitis.
    Sandborn WJ; Peyrin-Biroulet L; Zhang J; Chiorean M; Vermeire S; Lee SD; Kühbacher T; Yacyshyn B; Cabell CH; Naik SU; Klassen P; Panés J
    Gastroenterology; 2020 Feb; 158(3):550-561. PubMed ID: 31711921
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Measuring the symptom burden of lung cancer: the validity and utility of the lung cancer module of the M. D. Anderson Symptom Inventory.
    Mendoza TR; Wang XS; Lu C; Palos GR; Liao Z; Mobley GM; Kapoor S; Cleeland CS
    Oncologist; 2011; 16(2):217-27. PubMed ID: 21285393
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial.
    Peyrin-Biroulet L; Hart A; Bossuyt P; Long M; Allez M; Juillerat P; Armuzzi A; Loftus EV; Ostad-Saffari E; Scalori A; Oh YS; Tole S; Chai A; Pulley J; Lacey S; Sandborn WJ;
    Lancet Gastroenterol Hepatol; 2022 Feb; 7(2):128-140. PubMed ID: 34798039
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.